

Patent families (FamPat) - 32 results

#		 Title	Publication number	1st app. date	Applicant/Assignee				
1.		Combination therapy comprising a mat2a inhibitor and type i prmt inhibitor	US20240269143	2022-06-01	 GLAXOSMITHKLINE	 IDEAYA BIOSCIENCES		 GLAXOSMITHKLINE INTELLECTUAL PROPERTY	
2.		Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor	US20240108626	2023-11-03	 IDEAYA BIOSCIENCES			99 %	
3.		Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor	EP4347569	2022-06-01	 IDEAYA BIOSCIENCES			96 %	
4.		Quinazoline methionine adenosine transferase 2A inhibitor	CN116283799	2022-12-15	 NANJING CHIA TAI TIANQING PHARMACEUTICAL			96 %	
5.		Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors	US20240208965	2021-06-09	 IDEAYA BIOSCIENCES			95 %	
6.		Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer	US12077534	2019-12-27	 LES LABORATOIRES SERVIER	 AGIOS PHARMACEUTICALS		94 %	
7.		Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer	US11524960	2019-03-28	 LES LABORATOIRES SERVIER	 AGIOS PHARMACEUTICALS	 SERVIER PHARMACEUTICALS	94 %	
8.		2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors	US11046691	2019-12-09	 IDEAYA BIOSCIENCES	 IDEYA BIOSCIENCES		93 %	
9.		Oxo quinazoline compound and application thereof	CN116283800	2023-05-16	 INSILICO MEDICINE			93 %	
10.		Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof	US11999713	2022-10-19	 INSILICO MEDICINE IP	 HONG KONG SUNTECH INTELLIGENT	 INSILICO MEDICINE SHIN IP	91 %	
11.		N-phenyl-2-oxo quinazoline compound and application thereof	CN116239541	2023-05-11	 INSILICO MEDICINE			90 %	
12.		Inhibitors of cellular metabolic processes	US10329298	2016-08-31	 SERVIER PHARMACEUTICALS	 AGIOS PHARMACEUTICALS	 LES LABORATOIRES SERVIER	88 %	 VIVA BIOTECH
13.		Amidopyrimidone derivatives	US20230227449	2021-06-21	 EXSCIENTIA GREAT BRITAIN	 HOFFMANN LA ROCHE		87 %	
14.		Pharmaceutical combination of prmt5 inhibitors	US20220395508	2020-10-22	 LUPIN			87 %	
15.		Tricyclic compounds and uses thereof	WO2024/002024	2023-06-26	 CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG			86 %	
16.		2-oxoquinazoline five-membered heterocyclic derivative as well as preparation method and application thereof	CN116903613	2023-04-19	 CHENGDU CHIPSCREEN PHARMACEUTICAL	 SHENZHEN CHIPSCREEN BIOSCIENCES		86 %	
17.		Heterocyclic compound and application thereof	CN117624063	2022-08-16	 SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES			86 %	
18.		Methionine adenosyltransferase 2a inhibitors	WO2023/196985	2023-04-07	 IDEAYA BIOSCIENCES			86 %	
19.		Methionine adenosyltransferase 2a inhibitor and medical use thereof	WO2024/183778	2024-03-07	 GAN LEE PHARM			85 %	
20.		Methionine adenosyltransferase 2a inhibitor	US20240287063	2022-05-31	 NANJING CHIA TAI TIANQING PHARMACEUTICAL	 NANJING CHIA TAIYO PHARMACEUTICAL		84 %	
21.		Substituted pyridone compound and application	WO2022/078403	2021-10-13	 JIANGSU SIMCERE PHARM	 NANJING ZAIMING PHARMACEUTICAL		84 %	
22.		Preparation method for class of nitrogen-containing fused ring compounds and use thereof	WO2022/052924	2021-09-07	 SHANGHAI RINGENE BIOPHARMA			81 %	
23.		Methionine adenosyltransferase 2a heterocyclic inhibitor	EP4434989	2022-12-20	 NANJING CHIA TAI TIANQING PHARMACEUTICAL	 NJING CHIA TAI TIANQING PHARMACEUTICAL		81 %	
24.		Phenylethynyl-substituted benzenes and heterocycles for the treatment of cancer	US10449186	2018-05-10	 UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION			80 %	
25.		Fused-glutarimide crbn ligands and uses thereof	US20220281831	2020-07-15	 KYMERA THERAPEUTICS			70 %	
26.		Amide compound, pharmaceutical composition containing amide compound, and preparation method and application of amide compound	CN118221682	2024-03-19	 SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL			69 %	
27.		Conjugated proteins and uses thereof	US20200278355	2018-09-27	 SCRIPPS RESEARCH INSTITUTE			61 %	
28.		Biomarker compositions and methods	US20140220580	2012-06-14	 CARIS LIFE SCIENCES SWITZERLAND HOLDINGS	 CARIS LIFE SCIENCES LUXEMBOURG HOLDINGS		57 %	
29.		Covalent Binding Compounds for the Treatment of Disease	US20240165239	2023-09-05	 HYKU BIOSCIENCES			54 %	
30.		Covalent binding compounds for the treatment of disease	EP4301359	2022-03-04	 UMBRA THERAPEUTICS	 HYKU BIOSCIENCES		49 %	
31.		Substrate adaptor inhibitors of prmt5 and uses thereof	WO2022/032144	2021-08-06	 BROAD INSTITUTE OF MIT & HARVARD	 DANA FARBER CANCER INSTITUTE		45 %	

▶ CARIS LIFE SCIENCES SWITZERLAND HOLDINGS

CARIS LIFE SCIENCES

CARIS LIFE SCIENCES LUXEMBOURG HOLDINGS

CARIS MPI

CHARIS LIFE SCIENCES HOLDINGS LUXEMBOURG SHIZU